Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

ABSTRACT: Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease - an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.

SUBMITTER: Renner A 

PROVIDER: S-EPMC8273398 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature